RESUMO
A 69-year-old man underwent distal gastrectomy in September 2007 for type 2 gastric cancer with liver metastasis (S5) in LM area (p-T2N3aM1, Stage IV). After the operation, we performed chemotherapy. But the liver metastasis was enlarged, so we performed a partial hepatectomy in July 2008. After hepatectomy, liver metastases appeared on S6 and S7 in February 2009. So we performed the fifth-line chemotherapy with paclitaxel. The effect of paclitaxel was not so good. Therefore, SBRT was performed for the liver metastases (S6/7 and S7) in December 2009 and February 2010. After SBRT, he had no recurrent tumor. SBRT was one of the effective treatments for liver metastases from gastric cancer.
Assuntos
Neoplasias Hepáticas/radioterapia , Técnicas Estereotáxicas , Neoplasias Gástricas/terapia , Idoso , Quimiorradioterapia , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Masculino , Terapia de Salvação , Neoplasias Gástricas/patologia , Tomografia Computadorizada por Raios XRESUMO
A 74-year-old female was performed distal gastrectomy (f-T3N0H0P0CY0M0, Stage II) for gastric cancer in 2003. After 14 months, CT scan showed a metastasis in S7 segment of the liver. We performed chemotherapies until seventh-line and radio-frequency ablation (RFA). It finally got a long-term survival of 36 months postoperatively. RFA may be one of the useful therapies of liver metastasis from gastric cancer.
Assuntos
Gastrectomia , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Neoplasias Gástricas/patologia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ablação por Cateter , Terapia Combinada , Feminino , Humanos , Neoplasias Gástricas/cirurgiaRESUMO
A-57-year-old male was performed a total gastrectomy (f-T3N2H0P1CY1M0, Stage IV) for gastric cancer in 2004. We kept performing chemotherapies until the seventh-line, and the patient at last had a long-term survival of 46 months after surgery. If we recognized a tumor that had a tendency to be progressive, the long-term survival may be obtained by changing a regimen as early as possible.
Assuntos
Neoplasias Gástricas/patologia , Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/sangue , Gastrectomia , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Gástricas/sangue , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/cirurgia , Fatores de Tempo , Falha de TratamentoRESUMO
A 62-year-old man was admitted for gastric cancer. He was performed a distal gastrectomy with Billroth I reconstruction in August 1999. Then he had remnant gastric cancer and metachronous liver cancer in November 2002. He was performed a total gastrectomy and partial hepatic resection. The histological findings of remnant stomach and liver cancer showed a same pattern of the primary gastric cancer. Another metachronous liver cancer appeared in March 2006. He was treated with chemotherapy using S-1 (day 1-21) and CDDP 20 mg/m2 (day 1, 8 and 15) q5w. The size of liver metastasis was kept the same for 16 months.
Assuntos
Neoplasias Hepáticas/secundário , Neoplasias Gástricas/patologia , Antineoplásicos/uso terapêutico , Gastrectomia , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Prognóstico , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/cirurgia , Taxa de Sobrevida , Fatores de TempoRESUMO
We evaluated the efficacy of gastrojejunostomy for patients with unresectable gastric cancer. Thirteen patients had undergone gastrojejunostomy (GJ group) and 14 patients who couldn't receive gastrojejunostomy, but had only been observed into their abdomen in the operation (S group). Between two groups, there were no significant differences in the effective rate, median survival time and the number of dates the patient stayed home after the operation. Gastrojejunostomy was useful for patients with a strong case of stenosis in the stomach, and may improve the quality of life as one of the multimodal therapy.